Cytosorbents CorpCTSOEarnings & Financial Report
Nasdaq · Health Care · Critical care
CytoSorbents Corporation is a publicly traded company located in Princeton, New Jersey.
Revenue
$8.6M
Gross Profit
$5.3M
Operating Profit
$-4.8M
Net Profit
$-2.8M
Gross Margin
61.0%
Operating Margin
-56.1%
Net Margin
-32.1%
YoY Growth
-2.2%
EPS
$-0.05
Cytosorbents Corp Q3 FY2024 Financial Summary
Cytosorbents Corp reported revenue of $8.6M (down 2.2% YoY) for Q3 FY2024, with a net profit of $-2.8M (up 69.9% YoY) (-32.1% margin). Cost of goods sold was $3.4M, operating expenses totaled $10.1M.
Key Financial Metrics
| Total Revenue | $8.6M |
|---|---|
| Net Profit | $-2.8M |
| Gross Margin | 61.0% |
| Operating Margin | -56.1% |
| Report Period | Q3 FY2024 |
Cytosorbents Corp Annual Revenue by Year
Cytosorbents Corp annual revenue history includes year-by-year totals (for example, 2025 revenue was $37.1M).
| Year | Annual Revenue |
|---|---|
| 2025 | $37.1M |
| 2024 | $35.6M |
| 2023 | $31.1M |
| 2022 | $34.7M |
Cytosorbents Corp Quarterly Revenue & Net Profit History
Cytosorbents Corp results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $9.2M | +0.9% | $-5.5M | -59.5% |
| Q3 FY2025 | $9.5M | +10.1% | $-3.2M | -33.4% |
| Q2 FY2025 | $9.6M | +8.8% | $1.9M | 20.2% |
| Q1 FY2025 | $8.7M | -2.9% | $-1.5M | -16.9% |
| Q4 FY2024 | $9.2M | +168.8% | $-7.6M | -82.7% |
| Q3 FY2024 | $8.6M | -2.2% | $-2.8M | -32.1% |
| Q2 FY2024 | $8.8M | -6.1% | $-4.3M | -48.6% |
| Q1 FY2024 | $9.0M | -4.9% | $-6.1M | -67.7% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $9.0M | $8.8M | $8.6M | $9.2M | $8.7M | $9.6M | $9.5M | $9.2M |
| YoY Growth | -4.9% | -6.1% | -2.2% | 168.8% | -2.9% | 8.8% | 10.1% | 0.9% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $47.1M | $53.4M | $47.8M | $47.4M | $50.8M | $48.0M | $45.8M | $44.2M |
| Liabilities | $27.4M | $36.0M | $34.7M | $36.3M | $36.2M | $36.4M | $36.7M | $38.3M |
| Equity | $19.6M | $17.4M | $13.4M | $11.1M | $14.5M | $11.6M | $9.0M | $5.9M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-4.8M | $-4.8M | $-2.5M | $-2.3M | $-3.5M | $-1.5M | $-2.6M | $-4.8M |